ImmunityBio, Inc. IBRX Current ratio
Current ratio at other companies
Other financials
Where this comes from
Calculated from ImmunityBio, Inc.’s reported figures.
Based on the most recent quarter.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s current ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s current ratio?
- ImmunityBio, Inc. (IBRX) reported current ratio of 6.7× in Q1 2026.
- How has ImmunityBio, Inc.'s current ratio changed year-over-year?
- ImmunityBio, Inc.'s current ratio increased by 200.5% year-over-year, from 2.2× to 6.7×.
- What is the long-term trend for ImmunityBio, Inc.'s current ratio?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s current ratio has grown at a 25.5% compound annual growth rate (CAGR), from 1.6× to 5.1×.
- What does current ratio mean?
- Whether the company has enough short-term assets to cover its short-term bills.
- How do you interpret current ratio?
- Above 1.0 means short-term assets cover short-term liabilities. Very high values can signal idle cash or bloated inventory/receivables rather than strength — there's a healthy middle, not 'more is better'.
- How does current ratio compare across companies?
- Comparable within an industry. Working-capital-light businesses can operate safely below 1.0 by collecting before they pay.